Phase II study of dynamic tumor tracking IMRT in patients with locally advanced pancreatic cancer

Phase II study of dynamic tumor tracking intensity-modulated radiotherapy in patients with locally advanced pancreatic cancer - No Acronym

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051180237

Enrollment

Registered

2019-03-30

Start date

2015-09-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Chemotherapy Radiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pancreatic cancer pathologically proven with pancreatic juice or biops. 2) Clinical stage IIA, IIB, III (UICC) 3) ECOG PS;0-1 4) Without previous surgical resection for pancreatic cancer or irradiation to upper abdomen 5) adequate oral intake 6) Adequate organ functions; white blood cells >= 3,000/m3 Neutrophil>=2000/m3 platelets >= 100,000/m3 hemoglobin >= 9.0g/dl AST= 3.0 mg/dL Without fever over 38 degree 7) diagnosed as capable of dynamic tumor tracking with inserted fiducial marker 8) Written Informed Consent

Exclusion criteria

Exclusion criteria: 1) Intersitial pneumonia or pulmonary fibrosis 2) previous irradiation to upper abdomen 3) Severe comorbidity 4) Pleural effusion or Ascites 5) Tumor invasion to stomach, duodenum or intestine 6) Patients with double cancer (double cancer or treated cancer with no more than 3-year disease-free period). However, carcinoma in situ or intra-mucosal cancer-equivalent lesion are not to be included in double cancer 7) Severe allergy history to gold 8) Unstable and Uncontrollable diabetic mellitus, or severe collagen disease 9) Woman during pregnancy or breast-feeding, patient who wish pregnancy 10) Psychiatric disease 11) Inappropriate patients for this study judged by physicians

Design outcomes

Primary

Measure	Time frame
Freedom From Loco-regional Progression	—

Secondary

Measure	Time frame
Loco-regional Progression-free survival, Progression free survival, Overall survival, Acute toxicity, late toxicity	—

Countries

Japan, Japan Only

Contacts

Public ContactYoshimura Michio

Kyoto University, Graduate School of Medicine

myossy@kuhp.kyoto-u.ac.jp+81-75-751-3762

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026